Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Summary: Monoclonal antibodies have potential as rapidly developable agents for treatment and prevention of emerging viruses. The ACTIV-2 trial randomized persons with mild-moderate COVID-19 to the monoclonal antibody combination tixagevimab/cilgavimab via intramuscular injection (600 mg IM) or infu...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-03-01
Serie:	iScience
Ämnen:	Health sciences Medicine Medical specialty Immunology
Länkar:	http://www.sciencedirect.com/science/article/pii/S2589004225001981
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!